B cell activating factor (BAFF) and BAFF receptors: fakes and facts.
Gianfranco FerraccioliE GremesePublished in: Clinical and experimental immunology (2017)
Analysis of B cell activating factor (BAFF) receptors before and after B cell depletion therapy (BCDT) might offer a clue to the understanding of whether some B cell subsets may represent useful biomarkers of biological and clinical responses. Among the BAFF receptors in a cohort of rheumatoid arthritis (RA) patients, the AA have shown, by fluorescence activated cell sorter (FACS) analysis of median fluorescence intensity (MFI), that transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) and B cell maturation antigen (BCMA) do not change, whereas the most important, BAFF receptor 3 (BR3), appears to be decreased before as well as after BCDT in all B cell subsets but not in plasmablasts, the most important subset, depleted by BCDT.
Keyphrases
- rheumatoid arthritis
- signaling pathway
- end stage renal disease
- newly diagnosed
- single molecule
- peripheral blood
- ejection fraction
- disease activity
- prognostic factors
- peritoneal dialysis
- single cell
- ankylosing spondylitis
- cell therapy
- stem cells
- high intensity
- immune response
- energy transfer
- inflammatory response
- nuclear factor
- replacement therapy